Trial Profile
A Phase I/II Trial of BAY 43-9006 (Sorafenib) in Combination With Anastrozole in Patients With Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Anastrozole
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 11 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 04 Jan 2006 New trial record.